Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian , F. Stephen Hodi , Julie R. Brahmer , Suzanne L. Topalian , F. Stephen Hodi , Julie R. Brahmer , Scott Gettinger , David C. Smith , David F. McDermott , John D. Powderly , Richard D. Carvajal , Jeffrey A. Sosman , Michael B. Atkins , Philip D. Leming , David R. Spigel , Scott Antonia , Leora Horn , Charles G. Drake , Drew M. Pardoll , Lieping Chen , William H. Sharfman , Robert A. Anders , Janis M. Taube , Tracee L. McMiller , Haiying Xu , Alan J. Korman , Maria Jure–Kunkel , Shruti Agrawal , D. G. McDonald , Georgia Kollia , Ashok Gupta , Jon M. Wigginton , Mario Sznol
2012 New England Journal of Medicine 12,335 citations

Abstract

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use. Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00730639.).

Keywords

MedicineAdverse effectMelanomaCancerInternal medicineLung cancerImmune systemProstate cancerGastroenterologyAntibodyRenal cell carcinomaOncologyImmunologyCancer research

Affiliated Institutions

Related Publications

Publication Info

Year
2012
Type
article
Volume
366
Issue
26
Pages
2443-2454
Citations
12335
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

12335
OpenAlex

Cite This

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. (2012). Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. New England Journal of Medicine , 366 (26) , 2443-2454. https://doi.org/10.1056/nejmoa1200690

Identifiers

DOI
10.1056/nejmoa1200690